(Q45249011)

11 December 2017

title

Modulation of striatal dopamine release by glycine transport inhibitors (English)

1 reference

11 December 2017

0 references

1 reference

1

Daniel C Javitt

1 reference

11 December 2017

Audrey Hashim

2

1 reference

11 December 2017

Henry Sershen

series ordinal

3

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 April 2005

1 reference

11 December 2017

published in

Neuropsychopharmacology

1 reference

11 December 2017

volume

30

1 reference

11 December 2017

issue

4

1 reference

11 December 2017

page(s)

649-656

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300589

11 December 2017

exact match

0 references

cites work

Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and [123I]iomazenil.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

The NMDA antagonist model for schizophrenia: promise and pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

γ-Aminobutyric acid (GABAB) receptor-mediated inhibition of tyrosine hydroxylase activity in the striatum of rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

GABAB receptor activation partially inhibits N-methyl-D-aspartate-mediated tyrosine hydroxylase stimulation in rat striatal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Subchronic continuous phencyclidine administration potentiates amphetamine-induced frontal cortex dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Modulation of N-methyl-D-aspartate receptor function by glycine transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

The glutamatergic dysfunction hypothesis for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Inhibition of gamma-aminobutyric acid uptake: anatomy, physiology and effects against epileptic seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Dopamine in schizophrenia: a review and reconceptualization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Ultrastructural immunocytochemical localization of the N-methyl-D-aspartate receptor and tyrosine hydroxylase in the shell of the rat nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Effects of activation of NMDA and AMPA glutamate receptors on the extracellular concentrations of dopamine, acetylcholine, and GABA in striatum of the awake rat: a microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Management of negative symptoms of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Glutamate as a therapeutic target in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Phaclofen: a peripheral and central baclofen antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Glutamatergic control of dopamine release in the rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Increased dopamine transmission in schizophrenia: relationship to illness phases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Striatal NMDA receptor subtypes: the pharmacology of N-methyl-D-aspartate-evoked dopamine, gamma-aminobutyric acid, acetylcholine and spermidine release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

NMDA receptor hypofunction model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Glutamate receptor agonists decrease extracellular dopamine in the rat nucleus accumbens in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

GABA, glutamate and substance P-like immunoreactivity release: effects of novel GABAB antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

D-serine added to antipsychotics for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

Presynaptic glutamate receptors modulate dopamine release from striatal synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Regulation of NMDA-stimulated [14C]GABA and [3H]acetylcholine release by striatal glutamate and dopamine receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: implications for schizophrenia and substance abuse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Inhibition of striatal dopamine release by glycine and glycyldodecylamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Direct observation of dopamine compartmentation in striatal nerve terminal by 'in vivo' measurement of the specific activity of released dopamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Glutamatergic animal models of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Allosteric modulation of N-methyl-D-aspartate receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Positron emission tomography studies of potential mechanisms underlying phencyclidine-induced alterations in striatal dopamine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Centrally-administered glycine antagonists increase locomotion in monoamine-depleted mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Inhibitory glutamatergic regulation of evoked dopamine release in striatum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300589

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300589

1 reference

Dimensions Publication ID

11 December 2017

1044931668

0 references

1 reference